GlaxoSmithKline Consumer Healthcare Pakistan Limited Financial Results for the Half Year Ended 30 June 2022

The Board of Directors of our Company in their meeting held on Tuesday, 23 August 2022 at 11.00 a.m., at Marriott Hotel, Islamabad and via weblink, recommended the following:




(i)                  CASH DIVIDEND          NIL

 
 AND/OR
 
(ii)        BONUS SHARES             NIL



https://upload.wikimedia.org/wikipedia/en/thumb/f/f8/GSK_logo_svg.svg/1200px-GSK_logo_svg.svg.png* This includes super tax including deferred tax charge amounting to Rs. 283 million and Rs. 62 million for tax years 2022 and 2023 respectively on account of super tax. The unadjusted EPS stands at Rs.

5.32 compared to the adjusted EPS of Rs. 2.37.


Post a Comment

Previous Post Next Post